CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Medium Chain Triglyceride solution +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06588972
NCT06588972Phase 2Completed

Analgesic Effects of a Treatment With Cannabis Sativa Extract in Patients With Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis)

Federal University of Latin American Integration·interventional·Posted Sep 19, 2024·Updated Jul 2, 2025

In Brief

A Phase 2 clinical trial evaluating Medium Chain Triglyceride solution and Cannabis Sativa for OSTEOARTHRITIS OF THE KNEE. Completed, enrolled 45 participants across 1 site.

Detailed Summary

Osteoarthritis (OA) is the most prevalent joint disease in humans, often causing disability in affected individuals, especially the elderly. OA is characterized by mechanical joint pain, crepitus and short-term post-immobilization stiffness. OA pain has a variable pathophysiology and, despite the many pharmacological options available, its treatment is often ineffective and has significant side effects. The search for more effective and safer treatments is therefore essential in the field of OA. Among the possible treatments are substances derived from cannabis. Cannabis plants have been used for various purposes by humankind for thousands of years. Its best-known species, Cannabis sativa, has more than a hundred substances called cannabinoids or, more specifically, phytocannabinoids, the most important of which is cannabidiol (CBD). Although many pre-clinical studies indicate the usefulness of phytocannabinoids, clinical evidence for their application is currently scarce. Therefore, this project aims to investigate the effects of a CBD-rich extract of Cannabis sativa on the pain of patients with knee OA, as well as the possible adverse events of this treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedSep 19, 2024
Enrollment StartJan 1, 2024
Primary CompletionOct 10, 2024
Study CompletionOct 12, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.8 years ago

Interventions

Medium Chain Triglyceride solutiondietary

Placebo

Cannabis Sativaother

Group 2: Cannabis sativa extract with CBD (45mg/day).